UNICREDIT BANK/CALL/ASTRAZENECA/13000/0.1/18.06.25 | Market Closed - Börse Stuttgart 19:07:26 24/05/2024 BST | ||
| 1.3 EUR | 0.00% |
|
| Current month | +18.18% | ||
| 1 month | +66.67% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24/05/24 | 1.3 | 0.00% |
| 23/05/24 | 1.3 | +2.36% |
| 22/05/24 | 1.27 | +7.63% |
| 21/05/24 | 1.18 | +6.31% |
| 20/05/24 | 1.11 | -1.77% |
Delayed Quote Börse Stuttgart
Last update May 24, 2024 at 07:07 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
UniCredit
|
| WKN | HD1H8B |
| ISIN | DE000HD1H8B6 |
| Date issued | 28/12/2023 |
| Strike | 13,000 p |
| Maturity | 18/06/2025 (388 Days) |
| Parity | 10 : 1 |
| Emission price | 0.58 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.36 € |
|---|---|
| Lowest since issue | 0.2 € |
| Spread | 0.03 € |
| Spread % | 2.27% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
156.7
USD
Average target price
170.1
USD
Spread / Average Target
+8.53%
- Stock Market
- Warrants
- Warrant
